Skip to main content

Major Life Science Announcements Show Greater Houston Region’s Momentum

Published Oct 20, 2023 by Hailea Schultz

Alexandria Center

Rendering of the Alexandria Center for Advanced Technologies

Two recent announcements, including a new life sciences campus opening in The Woodlands and an international company opening a biotech facility at Houston’s Levit Green, are a testament to the greater Houston region’s momentum in the life sciences industry. 

The Alexandria Center for Advanced Technologies, a 12-acre life sciences campus, recently opened in The Woodlands at the former Lexicon Pharmaceuticals campus. The innovative development features the first purpose-built, cost-effective Class A laboratory infrastructure in the area. Additionally, the campus includes a suite of amenities, including conference and event space, a four-story parking garage, a courtyard and lawn, and a wellness and fitness center with pickleball courts. 

Anchor tenant Nurix Therapeutics, a San Francisco-based clinical-stage biopharmaceutical, has moved into one of the first buildings. Nurix focuses on protein modulation to treat cancer and other challenging diseases. 

"The Woodlands offers us a business-friendly, entrepreneurial environment that is critical to our growth,” said Arthur T. Sands, president and CEO of Nurix. “Alexandria's thoughtfully designed new campus provides us with state-of-the-art laboratory space and dynamic amenities that are key to helping us attract and retain top talent as we work to change the future of medicine through an exciting new modality of treating disease: targeted protein modulation." 

According to the Houston Business Journal, the campus is still being built out but will ultimately offer an additional 325,000 square feet of building space and employ more than 1,000 workers.  

The California-based real estate firm behind the new campus, Alexandria Real Estate Equities, said it is “committed to developing a commercial life science presence in The Woodlands,” like it did in New York City in 2010. As part of Alexandria’s strategic efforts, it is also extending its funding arm, the Alexandria Seed Capital Platform, to The Woodlands. 

"Our expansion into Greater Houston, and The Woodlands in particular, creates a unique opportunity to help bolster the ecosystem's startup community,” said Jenna Foger, senior vice president of science and technology at Alexandria Real Estate Equities and Alexandria Venture Investments. “Through our leading strategic venture investment and seed capital platforms, we will engage local scientists and entrepreneurs to identify new technologies and companies for seed- and early-stage investment and introduce those that are most promising to our unparalleled network of biopharmaceutical industry experts and venture advisors to accelerate innovation in The Woodlands."

Alexandria’s new life sciences campus follows other announcements from California-based companies. Last year, Cellipont Bioservices announced it was building a 76,000-square-foot manufacturing facility. 

In addition to the life science activity in The Woodlands, Houston recently attracted an international company. 

Sino Biological, a leading biotech company headquartered in Beijing, China, announced the opening of its Center for Bioprocessing (C4B) at Levit Green, Houston’s 53-acre master-planned life sciences district.

The new center marks the company’s first U.S.-based manufacturing facility. CB4 will feature 10,000 square feet of commercial lab and office space and focus on contract research services, including custom recombinant protein and recombinant antibody development and manufacture.

“With the establishment of our new Center for Bioprocessing here in Houston, we are excited to mark a significant milestone in Sino Biological’s global presence,” said Dr. Yingmin Zhu, Head of the new C4B. “As the leader of C4B, I’m thrilled to share that our center is poised to revolutionize the field of bioprocessing. [Our team] looks forward to partnering with researchers and industry leaders worldwide to forge a brighter future in the life sciences.”

Strategically located in Building I at Levit Green, a 290,000-square-foot, five-story building adjacent to the world-renowned Texas Medical Center, Sino Biological will have the advantage of connecting with the region’s top researchers and professionals. 

“Sino Biological’s expansion to Houston will further enhance Houston’s thriving life sciences and biotechnology ecosystem,” said Bob Harvey, president and CEO of the Greater Houston Partnership. “The presence of the company’s Center for Bioprocessing at Levit Green is a great example of the types of companies choosing to scale their operations in Houston at our cutting-edge life science facilities. We are pleased to welcome them to Houston.”

The Partnership actively works to bring top talent and businesses to the greater Houston region. Sino Biological is one of the many companies the Partnership has played a vital role in attracting to the Bayou City by providing potential site selections and market research. 

Discover Houston’s life sciences sector.

Related News

Health Care

University of Houston, Baylor College of Medicine to Launch Cutting-Edge Research Hub

8/26/24
The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry. 
Read More
Life Sciences

Rice University Awarded $18 Million to Advance Tumor Removal Technology

8/16/24
A research initiative led by Rice University, in collaboration with The University of Texas MD Anderson, has received an $18 million grant from the Advanced Research Projects Agency for Health (ARPA-H). The funding, which will be distributed over five years, will support the development of a new system aimed at enhancing the accuracy of tumor removal in breast, and head and neck cancer.   Rice University was among eight institutions chosen to receive a share of the $150 million in grants announced earlier this week by the Biden-Harris administration. This funding is part of the ongoing Cancer Moonshot initiative, which seeks to halve the cancer death rate by 2047.   The Rice and MD Anderson research team has developed a groundbreaking cancer pathology system called AccessPath, which addresses a significant challenge surgeons face: accurately identifying the margin where a tumor ends, and healthy tissue begins. Leveraging advanced technologies, including a high-resolution microscope and advanced artificial intelligence algorithms, AccessPath enables surgeons to determine in real time whether they have completely removed a tumor during surgery.  “Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Rebecca Richards-Kortum, a lead researcher on the project and director of the Rice360 Institute for Global Health Technologies, said in a news release.  According to ARPA-H, nearly two million Americans are diagnosed with cancer each year. Given the complexity and high cost of cancer treatment, AccessPath offers a promising solution by “reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes,” said Dr. Ana Paula Refinetti, an associate professor in the Breast Surgical Oncology department at MD Anderson and one of the lead researchers on the project.  This cutting-edge innovation stems from a strategic partnership established this summer between Rice University and MD Anderson. Through the Cancer Bioengineering Collaborative, the two institutions are working together to develop life-saving technologies and bioengineering strategies to enhance cancer research, diagnosis and treatment.  “AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” said Ramamoorthy Ramesh, Rice’s executive vice president for research. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center.”  This award is yet another example showcasing Houston’s leadership in advancing critical, life-saving technologies.  Learn more about Houston’s life sciences industry. 
Read More

Related Events

Economic Development

Life Sciences and Biotechnology Forum

The synthetic biology market, driven by research and development, is expected to grow significantly, with estimates suggesting it could reach $30 billion or more by 2030. Synthetic biology has the potential to…

Learn More
Learn More
Executive Partners